Sep 11, 2026, 00:41 UTC
Seikagaku Corporation shares fell sharply for a fourth consecutive session, hitting a year-to-date low, after the company disclosed the FDA Complete Response Letter for Condoliase.
Source:Sep 10, 2026, 11:00 UTC
Seikagaku Corporation received a complete response letter from the FDA regarding its US approval application for the lumbar disc herniation treatment SI-6603.
Aug 5, 2026, 07:00 UTC
Seikagaku Corporation announced its first-quarter results for April-June 2026, reporting an ordinary profit of 100 million yen, a turnaround from a 130 million yen loss in the same period last year.
Source: